Recently, the multi-center Phase Ib/II clinical trial of LW231 – the world's first bi-functional and dual-target drug independently developed by Longwood for complete cure of hepatitis B – has successfully enrolled its first subject.
Recently, the multi-center Phase Ib/II clinical trial of LW231 – the world's first bi-functional and dual-target drug independently developed by Longwood for complete cure of hepatitis B – has successfully enrolled its first subject.